Evolus Competitors

Xencor (NASDAQ:XNCR) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

21.7% of Evolus shares are held by institutional investors. 3.7% of Xencor shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Xencor and Evolus' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Xencor and Evolus, as provided by MarketBeat.

Xencor presently has a consensus price target of $47.1111, suggesting a potential upside of 16.41%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Xencor's stronger consensus rating and higher probable upside, research analysts plainly believe Xencor is more favorable than Evolus.

Earnings & Valuation

This table compares Xencor and Evolus' gross revenue, earnings per share and valuation.

Xencor has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xencor has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Summary

Xencor beats Evolus on 9 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. Comparatively, 21.7% of Evolus shares are held by institutional investors. 2.8% of Amarin shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amarin and Evolus' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Evolus, as provided by MarketBeat.

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 88.56%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Amarin's stronger consensus rating and higher probable upside, research analysts plainly believe Amarin is more favorable than Evolus.

Earnings & Valuation

This table compares Amarin and Evolus' gross revenue, earnings per share and valuation.

Amarin has higher revenue and earnings than Evolus. Amarin is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Summary

Amarin beats Evolus on 10 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arcus Biosciences and Evolus, as provided by MarketBeat.

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 59.45%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than Evolus.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 21.7% of Evolus shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Profitability

This table compares Arcus Biosciences and Evolus' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Arcus Biosciences and Evolus' gross revenue, earnings per share and valuation.

Arcus Biosciences has higher earnings, but lower revenue than Evolus. Arcus Biosciences is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Summary

Arcus Biosciences beats Evolus on 11 of the 14 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and Prestige Consumer Healthcare, as provided by MarketBeat.com.

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 100.23%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Evolus and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Evolus and Prestige Consumer Healthcare's gross revenue, earnings per share and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Prestige Consumer Healthcare beats Evolus on 9 of the 14 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and IGM Biosciences, as provided by MarketBeat.com.

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. IGM Biosciences has a consensus target price of $98.8750, suggesting a potential upside of 44.36%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500.

Profitability

This table compares Evolus and IGM Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Evolus and IGM Biosciences' gross revenue, earnings per share and valuation.

IGM Biosciences has lower revenue, but higher earnings than Evolus. IGM Biosciences is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Evolus on 9 of the 13 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and Revance Therapeutics, as provided by MarketBeat.com.

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Revance Therapeutics has a consensus target price of $36.40, suggesting a potential upside of 29.40%. Given Revance Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Revance Therapeutics is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Evolus and Revance Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Evolus and Revance Therapeutics' gross revenue, earnings per share and valuation.

Evolus has higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.